# Abdullah M Ali

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4314581/publications.pdf

Version: 2024-02-01

| 46 | 1,926 | 394421 | 302126 |
|---|---|---|---|
| papers | citations | 19 h-index | 39 g-index |

| 48 | 48 | 48 | 3420 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell, 2016, 30, 404-417. | 16.8 | 318 |
| 2 | BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicaseâ€“double Holliday junction dissolvasome. Genes and Development, 2008, 22, 2856-2868. | 5.9 | 187 |
| 3 | MHF1-MHF2, a Histone-Fold-Containing Protein Complex, Participates in the Fanconi Anemia Pathway via FANCM. Molecular Cell, 2010, 37, 879-886. | 9.7 | 178 |
| 4 | Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4726-34. | 7.1 | 175 |
| 5 | FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO Journal, 2007, 26, 2104-2114. | 7.8 | 130 |
| 6 | Impaired FANCD2 monoubiquitination and hypersensitivity to camptothecin uniquely characterize Fanconi anemia complementation group M. Blood, 2009, 114, 174-180. | 1.4 | 118 |
| 7 | U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3â€² End Formation. Molecular Cell, 2016, 62, 479-490. | 9.7 | 111 |
| 8 | Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11978-11987. | 7.1 | 90 |
| 9 | Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1. Molecular Cell, 2019, 76, 82-95.e7. | 9.7 | 84 |
| 10 | FAAP20: a novel ubiquitin-binding FA nuclear core-complex protein required for functional integrity of the FA-BRCA DNA repair pathway. Blood, 2012, 119, 3285-3294. | 1.4 | 78 |
| 11 | Role of CYP1B1, MYOC, OPTN, and OPTC genes in adult-onset primary open-angle glaucoma: predominance of CYP1B1 mutations in Indian patients. Molecular Vision, 2007, 13, 667-76. | 1.1 | 60 |
| 12 | ATR-Dependent Phosphorylation of FANCM at Serine 1045 Is Essential for FANCM Functions. Cancer Research, 2013, 73, 4300-4310. | 0.9 | 59 |
| 13 | DEK is required for homologous recombination repair of DNA breaks. Scientific Reports, 2017, 7, 44662. | 3.3 | 30 |
| 14 | Human MutS and FANCM complexes function as redundant DNA damage sensors in the Fanconi Anemia pathway. DNA Repair, 2011, 10, 1203-1212. | 2.8 | 26 |
| 15 | SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 7.1 | 26 |
| 16 | FANCMâ€“FAAP24 and FANCJ: FA proteins that metabolize DNA. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 668, 20-26. | 1.0 | 25 |
| 17 | Ectopic HOXB4 overcomes the inhibitory effect of tumor necrosis factor-Î± on Fanconi anemia hematopoietic stem and progenitor cells. Blood, 2009, 113, 5111-5120. | 1.4 | 25 |
| 18 | Mutation and polymorphism analysis of TSC1 and TSC2 genes in Indian patients with tuberous sclerosis complex. Acta Neurologica Scandinavica, 2005, 111, 54-63. | 2.1 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Identification and characterization of mutations in FANCL gene: A second case of Fanconi anemia belonging to FA-L complementation group. Human Mutation, 2009, 30, E761-E770. | 2.5 | 23 |
| 20 | Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes. Blood Advances, 2018, 2, 1393-1402. | 5.2 | 20 |
| 21 | Mutation analysis of the KIF21A gene in an Indian family with CFEOM1: implication of CpG methylation for most frequent mutations. Ophthalmic Genetics, 2004, 25, 247-255. | 1.2 | 19 |
| 22 | The nuclear DEK interactome supports multiâ€functionality. Proteins: Structure, Function and Bioinformatics, 2018, 86, 88-97. | 2.6 | 19 |
| 23 | Rewriting the rules for care of MDS and AML patients in the time of COVID-19. Leukemia Research Reports, 2020, 13, 100201. | 0.4 | 14 |
| 24 | Improving Treatment for Myelodysplastic Syndromes Patients. Current Treatment Options in Oncology, 2018, 19, 66. | 3.0 | 12 |
| 25 | Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 1106-1127. | 9.4 | 12 |
| 26 | Identification of a core promoter and a novel isoform of the human TSC1 gene transcript and structural comparison with mouse homolog. Gene, 2003, 320, 145-154. | 2.2 | 10 |
| 27 | Characterization of the human SLC22A18 gene promoter and its regulation by the transcription factor Sp1. Gene, 2009, 429, 37-43. | 2.2 | 7 |
| 28 | Monopolar Spindle 1 (MPS1) Protein-dependent Phosphorylation of RecQ-mediated Genome Instability Protein 2 (RMI2) at Serine 112 Is Essential for BLM-Topo III Î±-RMI1-RMI2 (BTR) Protein Complex Function upon Spindle Assembly Checkpoint (SAC) Activation during Mitosis. Journal of Biological Chemistry, 2013, 288, 33500-33508. | 3.4 | 7 |
| 29 | Loss of Faap20 Causes Hematopoietic Stem and Progenitor Cell Depletion in Mice Under Genotoxic Stress. Stem Cells, 2015, 33, 2320-2330. | 3.2 | 7 |
| 30 | Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells. Medical Oncology, 2022, 39, 65. | 2.5 | 7 |
| 31 | Survey and evaluation of mutations in the human KLF1 transcription unit. Scientific Reports, 2018, 8, 6587. | 3.3 | 5 |
| 32 | Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses. Blood, 2013, 122, 2745-2745. | 1.4 | 5 |
| 33 | Two different â€œtalesâ€•of ATG7: Clinical relevance to myelodysplastic syndromes. Molecular and Cellular Oncology, 2016, 3, e1212686. | 0.7 | 3 |
| 34 | Rigosertib in myelodysplastic syndromes (MDS). Expert Opinion on Orphan Drugs, 2016, 4, 981-988. | 0.8 | 2 |
| 35 | Loss of TET2 Function in Myelodysplastic Syndrome Results in Intragenic Hypermethylation and Alterations in mRNA Splicing. Blood, 2014, 124, 775-775. | 1.4 | 2 |
| 36 | Prognostic significance of neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in myelodysplastic syndromes.. Journal of Clinical Oncology, 2016, 34, 7062-7062. | 1.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Molecular Genetic Analysis of Myelodysplastic Syndromes (MDS) Patients with Ring Sideroblasts (RS); Independent Confirmation of Association of SF3B1 Mutations with Better Prognosis. Blood, 2014, 124, 3237-3237. | 1.4 | 2 |
| 38 | Pharmacological Targeting of Osteoblast-Induced MDS and AML. Blood, 2018, 132, 5235-5235. | 1.4 | 1 |
| 39 | A Targetable Bone Marrow-Niche Axis for the Treatment of Acute Myeloid Leukemia. Blood, 2021, 138, 4456-4456. | 1.4 | 1 |
| 40 | Current View of miRNA with Tumor Suppressor Function, Exploring MDS and AML as Models. Signal Transduction Insights, 2014, 3, STI.S12316. | 2.0 | 0 |
| 41 | 2016 - GENE EDITED STEM CELLS COMBINED WITH TARGETED IMMUNOTHERAPY: A NOVEL APPROACH TO TREAT MYELOID MALIGNANCIES. Experimental Hematology, 2019, 76, S46. | 0.4 | 0 |
| 42 | Challenges and Solutions to Bringing Chimeric Antigen Receptor T-Cell Therapy to Myeloid Malignancies. Cancer Journal (Sudbury, Mass ), 2021, 27, 143-150. | 2.0 | 0 |
| 43 | Comparison of International Prognostic Scoring System (IPSS) and Revised IPSS (IPSS-R) in myelodysplastic syndromes (MDS).. Journal of Clinical Oncology, 2016, 34, e18549-e18549. | 1.6 | 0 |
| 44 | Prognostic significance of bone marrow cellularity in myelodysplastic syndromes: a retrospective analysis.. Journal of Clinical Oncology, 2016, 34, e18550-e18550. | 1.6 | 0 |
| 45 | A Genomic Predictive Signature for Rigosertib in Lower Risk MDS Derived By Integrating Clinical Response, Mechanism of Action Data and Simulation. Blood, 2016, 128, 5535-5535. | 1.4 | 0 |
| 46 | Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas. Blood, 2019, 134, 2864-2864. | 1.4 | 0 |